FDA warned AG Hair Limited over CGMP failures for hand sanitizer drugs, including inadequate investigations, microbiological controls, and component testing.
What happened
FDA inspected AG Hair Limited's drug manufacturing facility from June 20 to 24, 2022, and reviewed the company's July 15, 2022 response to a Form FDA 483 (the inspection observation list). FDA found inadequate investigations of elevated bioburden and a customer complaint, missing microbiological testing and specifications for hand sanitizer, and inadequate component testing for ethanol and glycerin. FDA also said hand sanitizer shipments entered the U.S. after the company said it would cease production, and FDA placed the firm on Import Alert 66-40.
What FDA found
The firm did not thoroughly investigate an elevated bioburden sample before releasing a drug lot or a customer complaint about irritation, and its response did not include a retrospective review or CAPA effectiveness plan.
21 CFR 211.192The firm lacked adequate laboratory controls and microbiological testing and specifications for all non-sterile drug products, including no microbiological testing before release of Hands Free Clean Hand Sanitizer Gel.
21 CFR 211.160(b)The firm did not adequately test each component lot for identity and conformity, including ethanol identity, and did not test ethanol for methanol or glycerin for diethylene glycol (DEG).
21 CFR 211.84(d)(1) and 211.84(d)(2)
What FDA wants
FDA tells AG Hair to respond in writing within 15 working days with corrective actions, including independent assessments of its investigation and laboratory control systems, risk assessments and testing of affected lots, component testing plans, and clarification of whether it will stop U.S. hand sanitizer distribution and delist the products. FDA also recommends a qualified CGMP consultant.
Who should pay attention
- brands that buy finished drug products from AG Hair
- suppliers and users of ethanol or glycerin in drugs
- U.S. importers and distributors of hand sanitizer
This is a summary. Read the original letter on fda.gov.